Search

Your search keyword '"Rangarajan HG"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Rangarajan HG" Remove constraint Author: "Rangarajan HG"
56 results on '"Rangarajan HG"'

Search Results

1. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease.

2. Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis.

Catalog

Books, media, physical & digital resources

3. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.

4. Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis.

5. Isolated Optic Nerve Relapse in a Pediatric Patient With T-Cell Lymphoblastic Leukemia: A Brief Report.

6. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

7. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.

8. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.

9. No impact of CD34 + cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.

10. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.

11. Mixed donor chimerism following stem cell transplantation for sickle cell disease.

12. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers.

13. Long term survivor of MOZ-p300 therapy-related acute myeloid leukemia after matched unrelated donor bone marrow transplantation.

14. Effect of Autograft CD34 + Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors.

15. CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature.

16. Peritoneal and Pleural Drains in Pediatric Hematopoietic Cell Transplant Recipients with Veno-Occlusive Disease are Safe and Do Not Adversely Impact Clinical Outcomes.

17. Refractory, fatal autoimmune hemolytic anemia due to ineffective thymic-derived T-cell reconstitution following allogeneic hematopoietic cell transplantation for hypomorphic RAG1 deficiency.

18. Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency.

19. Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance.

22. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

23. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study.

24. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium.

25. Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease.

26. An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients.

27. A Novel Case of Concurrent T-cell and Early T-cell Precursor Lymphoblastic Lymphoma in an Adolescent Female.

28. Outcomes of pediatric patients with therapy-related myeloid neoplasms.

29. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

30. Pandemic-Related Shifts in New Patients Admitted to Children's Hospitals.

31. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

32. Delayed-Onset ADA1 (ADA) Deficiency Not Detected by TREC Screen.

33. Allogeneic Hematopoietic Cell Transplant for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.

34. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

35. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.

36. Costs of Cord Blood Transplantation Are Higher Than Other Graft Sources in Patients with Acute Leukemia and Myelodysplastic Syndrome Treated at Pediatric Centers.

37. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient.

38. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

39. A Novel Pathogenic Variant in CARMIL2 ( RLTPR ) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors.

40. Refractory Thrombocytopenia Is a Valid Early Diagnostic Criteria for Hepatic Veno-Occlusive Disease in Children.

41. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease.

42. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

43. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.

44. Monozygotic twins diagnosed simultaneously with RAM immunophenotype acute myeloid leukemia.

46. Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.

47. Successful second hematopoietic cell transplantation in severe congenital neutropenia.

48. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study.

49. 70% Ethanol for Decontamination of Central Venous Lines Exposed to Calcineurin Inhibitors.

50. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.